Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2012

View Archived Issues

Lycera presents new F1F0 ATPase inhibitors

F-14512 evaluated in phase I acute myeloid leukemia trial

HM-781-36B proves safe and well tolerated in patients with cancer

Amgen presents novel protein kinase inhibitors

Novel humanized antibodies reported by Seattle Genetics

Group at Nektar Therapeutics designs new analgesic agents

Amgen presents clinical results for ganitumab

Overall response rate over 80% seen in elotuzumab trial

Clinical data updated for ibrutinib

U.S. group discloses novel nitroxide derivatives

NIH awards funding for HIV vaccine research

Novel mGlu5 receptor modulators patented by Vanderbilt University

Lilly presents promising results for the gemcitabine prodrug LY-2334737

Arena Pharmaceuticals files for approval of lorcaserin in Switzerland

Merck & Co. provides update on phase III odanacatib trial

ImmunoGen commences first clinical trial of novel anticancer compound

GSK receives final phase III data for albiglutide

Actinium Pharmaceuticals gains licensing right to BC8 monoclonal antibody

PTC Therapeutics selects candidate to advance in collaboration with Wellcome Trust

Orexigen Therapeutics reports early enrollment in the Light study

Zogenix begins phase I trial of treatment candidate for schizophrenia

AstraZeneca forms alliance for Alzheimer's disease research

Cubist Pharmaceuticals begins first of two pivotal phase III trials of therapy for CDAD

AVI BioPharma changes name

PALACE-1 study of apremilast meets primary endpoint

OncoMed commences dosing in phase I trial of anticancer stem cell therapeutic

AstraZeneca acquires portfolio of neuroscience assets

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...